GlassScriptPhysician profile
Nina Talmor
NPI 1043874217
$817.60
in general payments reported to CMS, 2019-2025
13 companies · $466 in 2025
The $466 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $111 · 2024: $241 · 2025: $466.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $707.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $706.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $166.44 | 2025 | Cardiomems |
| Genzyme Corporation | $126.72 | 2024 | |
| Medtronic, INC. | $113.94 | 2025 | Symplicity G3 |
| Inari Medical, INC. | $91.33 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Astellas Pharma US INC | $81.99 | 2022 | |
| Edwards Lifesciences Corporation | $47.01 | 2025 | Sapien 3 Ultra Resilia |
| Amgen INC. | $31.69 | 2025 | Repatha |
| Merck Sharp & Dohme LLC | $29.04 | 2022 | |
| Lilly USA, LLC | $28.55 | 2025 | Zepbound |
| E.R. Squibb & Sons, L.L.C. | $28.55 | 2025 | Camzyos |
| Angiodynamics, INC. | $26.05 | 2025 | Angiovac |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.31 | 2025 | Jardiance |
| Pfizer INC. | $22.98 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nina Talmor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.